Biosimilars Market - Global Industry Analysis

Biosimilars Market- by Product (Recombinant non-glycosylated proteins, Recombinant peptides, Recombinant glycosylated proteins), by Manufacturing type (Contract manufacturing organizations, In-house manufacturing), by Application (Blood disorders, Growth hormone deficiency, Oncology, Chronic & autoimmune diseases, Infectious diseases, Others) - Global Industry Perspective Comprehensive Analysis and Forecast, 2020 - 2026

Published Date: 04-Dec-2020 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-1290 Status : Published

According to the report, global demand for Biosimilars market was valued at approximately USD 9.8 billion in 2019, and is expected to generate revenue of around USD 43.1 billion by end of 2026, growing at a CAGR of around 23.6 % between 2020 and 2026.

Description

According to the report, global demand for Biosimilars market was valued at approximately USD 9.8 billion in 2019, and is expected to generate revenue of around USD 43.1 billion by end of 2026, growing at a CAGR of around 23.6 % between 2020 and 2026.

Global Biosimilars Market: Overview

Biosimilar is a biopharmaceutical product which is similar to the previous or the original existing product that is manufactured by a company. The biosimilar also has alternative names such as subsequent entry biologic or follow-on biologic. When the patent of the original product expires biosimilars can be manufactured which are approved officially. When the patent expires of an approved recombinant drug any other biotech company can generate and market these biologics, thus the name biosimilars.

Global Biosimilars Market: Segmentation

The global biosimilars market is segmented into its product, manufacturing type and application. Based on the product, the market is segregated into recombinant non-glycosylated proteins, recombinant peptides, and recombinant glycosylated proteins. Further, the recombinant non-glycosylated proteins are sub-segmented into granulocyte colony-stimulating factor, interferons, insulin, and recombinant human growth hormones. The recombinant glycosylated proteins segment is sub-segmented into urofollitropin, erythropoietin, and monoclonal antibodies. the insulin and granulocyte colony-stimulating factor segment is sub-segmented into calcitonin and glucagon. On the basis of the manufacturing type, the market is categorized into contract manufacturing organizations and in-house manufacturing. On the basis of application, the market is divided into blood disorders, growth hormone deficiency, oncology, chronic & autoimmune diseases, infectious diseases, and others.

Global Biosimilars Market

Global Biosimilars Market: Growth Factors

The major factor that contributed to the biosimilars market growth is the emergence of the biologic products that are off-patent. These drugs are very cost-effective thus making its demand to increase substantially. In the coming years, this demand for the biosimilars is going to increase. The increasing rate of the diseases across the globe has also helped in contributing towards the market growth. The manufacturers of the biologic drug have started to take initiatives in making innovative strategies in order to develop the biosimilars market. Even though the market is in a phase where it is flourishing there are some restraining factors that are affecting the market growth. The factors such as lengthy clinical trials which are required from the regulatory bodies for approval and the production of biosimilars require complex infrastructure are affecting the market growth.

Global Biosimilars Market: Regional Analysis

The biosimilars market is geographically segmented into North America, Europe, Asia-Pacific, and Rest of the World. The region that is leading the biosimilars market is Europe and it accounts for the largest share in the global market. The factors that have attributed to this growth are Omni trope, bino crits, and lenograstim. Additionally, the strict regulatory framework and the increasing pipeline products estimate to contribute towards the growth of the European biosimilars market. There are opportunities increasing in the regions such as Asia Pacific region. As per the study, the Asia-Pacific region will have a progressive growth rate in the coming years. The stringent protocols in the US are hampering the biosimilars market in the North American region.

Global Biosimilars Market: Competitive Players

The key market players in the biosimilars market include Pfizer Inc., Teva Pharmaceuticals Industries Ltd., Biocon Ltd., F. Hoffmann-La Roche Ltd., Samsung Bioepis, Sandoz International GmbH, Amgen Inc., Dr. Reddy’s Laboratories Ltd. and Celltrion, Inc.

The report segments the Global Biosimilars market as follows:

Global Biosimilars Treatment Market: Product Segment Analysis

  • Recombinant non-glycosylated proteins
    • Granulocyte Colony-Stimulating Factor
    • Interferons
    • Insulin
    • Recombinant Human Growth Hormones
  • Recombinant peptides
  • Recombinant glycosylated proteins
    • Urofollitropin
    • Erythropoietin
    • Monoclonal antibodies

Global Biosimilars Treatment Market: Manufacturing type Segment Analysis

  • Contract manufacturing organizations
  • In-house manufacturing

Global Biosimilars Treatment Market: Application Segment Analysis

  • Blood disorders
  • Growth hormone deficiency 
  • Oncology
  • Chronic & autoimmune diseases
  • Infectious diseases
  • Others

Global Biosimilars Market: Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Biosimilars Market, 2016 - 2026, (USD Billion)
    • 2.2. Biosimilars Market: Snapshot
  • Chapter 3. Global Biosimilars Market – Industry Analysis
    • 3.1. Biosimilars Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Rising incidence of chronic diseases
      • 3.2.2. Increasing demand for biosimilar drugs
    • 3.3. Restraints
      • 3.3.1. Complexities in manufacturing
    • 3.4. Opportunity
      • 3.4.1. New indications and the patent expiry of biulogic products
    • 3.5. Porter’s Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis by Product segment
      • 3.6.2. Market attractiveness analysis by Manufacturing type segment
      • 3.6.3. Market attractiveness analysis by Application segment
      • 3.6.4. Market attractiveness analysis by regional segment
  • Chapter 4. Global Biosimilars Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Biosimilars market: company market share analysis, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Manufacturing type launches
      • 4.2.3. Agreements, partnerships, cullaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
  • Chapter 5. Global Biosimilars Market – Product Segment Analysis
    • 5.1. Global Biosimilars market overview: by Product
      • 5.1.1. Global Biosimilars market revenue share, by Product, 2019 and 2026
    • 5.2. Recombinant non-glycosylated proteins
      • 5.2.1. Global Biosimilars market by Recombinant non-glycosylated proteins, 2016-2026 (USD Billion)
    • 5.3. Recombinant peptides
      • 5.3.1. Global Biosimilars market by Recombinant peptides, 2016-2026 (USD Billion)
    • 5.4. Recombinant glycosylated proteins
      • 5.4.1. Global Biosimilars market by Recombinant glycosylated proteins, 2016-2026 (USD Billion)
  • Chapter 6. Global Biosimilars Market – Manufacturing type Segment Analysis
    • 6.1. Global Biosimilars market overview: by Manufacturing type
      • 6.1.1. Global Biosimilars market revenue share, by Manufacturing type, 2019 and 2026
    • 6.2. Contract manufacturing organizations
      • 6.2.1. Global Biosimilars market by Contract manufacturing organizations, 2016-2026 (USD Billion)
    • 6.3. In-house manufacturing
      • 6.3.1. Global Biosimilars market by In-house manufacturing, 2016-2026 (USD Billion)
  • Chapter 7. Global Biosimilars Market – Application Segment Analysis
    • 7.1. Global Biosimilars market overview: by Application
      • 7.1.1. Global Biosimilars market revenue share, by Application, 2019 and 2026
    • 7.2. Blood disorders
      • 7.2.1. Global Biosimilars market by Blood disorders, 2016-2026 (USD Billion)
    • 7.3. Growth hormone deficiency
      • 7.3.1. Global Biosimilars market by Growth hormone deficiency, 2016-2026 (USD Billion)
    • 7.4. Onculogy
      • 7.4.1. Global Biosimilars market by Onculogy, 2016-2026 (USD Billion)
    • 7.5. Chronic & autoimmune diseases
      • 7.5.1. Global Biosimilars market by Chronic & autoimmune diseases, 2016-2026 (USD Billion)
    • 7.6. Infectious diseases
      • 7.6.1. Global Biosimilars market by Infectious diseases, 2016-2026 (USD Billion)
    • 7.7. Others
      • 7.7.1. Global Biosimilars market by Others, 2016-2026 (USD Billion)
  • Chapter 8. Global Biosimilars Market - Regional Analysis
    • 8.1. Global Biosimilars market overview: by region
      • 8.1.1. Global Biosimilars market revenue share, by region, 2019 and 2026
    • 8.2. North America
      • 8.2.1. North America Biosimilars market, by country, 2016-2026 (USD Billion)
      • 8.2.2. North America Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
      • 8.2.3. North America Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
      • 8.2.4. North America Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
      • 8.2.5. The U.S.
        • 8.2.5.1. The U.S. Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
        • 8.2.5.2. The U.S. Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
        • 8.2.5.3. The U.S. Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
      • 8.2.6. Rest of North America
        • 8.2.6.1. Rest of North America Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
        • 8.2.6.2. Rest of North America Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
        • 8.2.6.3. Rest of North America Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
    • 8.3. Europe
      • 8.3.1. Europe Biosimilars market, by country, 2016-2026 (USD Billion)
      • 8.3.2. Europe Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
      • 8.3.3. Europe Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
      • 8.3.4. Europe Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
      • 8.3.5. U.K.
        • 8.3.5.1. U.K. Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
        • 8.3.5.2. U.K. Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
        • 8.3.5.3. U.K. Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
      • 8.3.6. France
        • 8.3.6.1. France Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
        • 8.3.6.2. France Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
        • 8.3.6.3. France Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
      • 8.3.7. Germany
        • 8.3.7.1. Germany Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
        • 8.3.7.2. Germany Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
        • 8.3.7.3. Germany Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
      • 8.3.8. Rest of Europe
        • 8.3.8.1. Rest of Europe Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
        • 8.3.8.2. Rest of Europe Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
        • 8.3.8.3. Rest of Europe Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Biosimilars market, by country, 2016-2026 (USD Billion)
      • 8.4.2. Asia Pacific Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
      • 8.4.3. Asia Pacific Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
      • 8.4.4. Asia Pacific Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
      • 8.4.5. China
        • 8.4.5.1. China Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
        • 8.4.5.2. China Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
        • 8.4.5.3. China Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
      • 8.4.6. Japan
        • 8.4.6.1. Japan Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
        • 8.4.6.2. Japan Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
        • 8.4.6.3. Japan Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
      • 8.4.7. India
        • 8.4.7.1. India Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
        • 8.4.7.2. India Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
        • 8.4.7.3. India Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
      • 8.4.8. Rest of Asia Pacific
        • 8.4.8.1. Rest of Asia Pacific Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
        • 8.4.8.2. Rest of Asia Pacific Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
        • 8.4.8.3. Rest of Asia Pacific Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
    • 8.5. Latin America
      • 8.5.1. Latin America Biosimilars market, by country, 2016-2026 (USD Billion)
      • 8.5.2. Latin America Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
      • 8.5.3. Latin America Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
      • 8.5.4. Latin America Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
      • 8.5.5. Brazil
        • 8.5.5.1. Brazil Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
        • 8.5.5.2. Brazil Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
        • 8.5.5.3. Brazil Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
      • 8.5.6. Rest of Latin America
        • 8.5.6.1. Rest of Latin America Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
        • 8.5.6.2. Rest of Latin America Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
        • 8.5.6.3. Rest of Latin America Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
    • 8.6. Middle East & Africa
      • 8.6.1. Middle East & Africa Biosimilars market, 2016-2026 (USD Billion)
      • 8.6.2. Middle East & Africa Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
      • 8.6.3. Middle East & Africa Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
      • 8.6.4. Middle East & Africa Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
  • Chapter 9. Company Profiles
    • 9.1. Pfizer Inc.
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Product Portfolio
      • 9.1.4. Business Strategy
      • 9.1.5. Recent Developments
    • 9.2. Teva Pharmaceuticals Industries Ltd.
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Product Portfolio
      • 9.2.4. Business Strategy
      • 9.2.5. Recent Developments
    • 9.3. Biocon Ltd
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Product Portfolio
      • 9.3.4. Business Strategy
      • 9.3.5. Recent Developments
    • 9.4. F. Hoffmann-La Roche Ltd.
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Product Portfolio
      • 9.4.4. Business Strategy
      • 9.4.5. Recent Developments
    • 9.5. Samsung Bioepis
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Product Portfolio
      • 9.5.4. Business Strategy
      • 9.5.5. Recent Developments
    • 9.6. Sandoz International GmbH
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Product Portfolio
      • 9.6.4. Business Strategy
      • 9.6.5. Recent Developments
    • 9.7. Amgen Inc
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Product Portfolio
      • 9.7.4. Business Strategy
      • 9.7.5. Recent Developments
    • 9.8. Dr. Reddy’s Laboratories Ltd
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Product Portfolio
      • 9.8.4. Business Strategy
      • 9.8.5. Recent Developments
    • 9.9. Celltrion, Inc.
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Product Portfolio
      • 9.9.4. Business Strategy
      • 9.9.5. Recent Developments

Table Of Figures

List of Figures

1. Market research process
2. Market research methodology
3. Global Biosimilars market, 2016-2026 (USD Billion)
4. Porter’s five forces analysis: Biosimilars market
5. Global Biosimilars market attractiveness, by Product
6. Global Biosimilars market attractiveness, by Manufacturing type
7. Global Biosimilars market attractiveness, by Application
8. Global Biosimilars market revenue share, by Product, 2019 and 2026
9. Global Biosimilars market by Recombinant non-glycosylated proteins, 2016-2026 (USD Billion)
10. Global Biosimilars market by Recombinant peptides, 2016-2026 (USD Billion)
11. Global Biosimilars market by Recombinant glycosylated proteins, 2016-2026 (USD Billion)
12. Global Biosimilars market revenue share, by Manufacturing type, 2019 and 2026
13. Global Biosimilars market by Contract manufacturing organizations, 2016-2026 (USD Billion)
14. Global Biosimilars market by In-house manufacturing, 2016-2026 (USD Billion)
15. Global Biosimilars market revenue share, by Application, 2019 and 2026
16. Global Biosimilars market by Blood disorders, 2016-2026 (USD Billion)
17. Global Biosimilars market by Growth hormone deficiency, 2016-2026 (USD Billion)
18. Global Biosimilars market by Growth hormone deficiency, 2016-2026 (USD Billion)
19. Global Biosimilars market by Oncology, 2016-2026 (USD Billion)
20. Global Biosimilars market by Chronic & autoimmune diseases, 2016-2026 (USD Billion)
21. Global Biosimilars market by Infectious diseases, 2016-2026 (USD Billion)
22. Global Biosimilars market by Others, 2016-2026 (USD Billion)
23. Global Biosimilars market revenue share, by region, 2018 & 2025
24. North America Biosimilars market, 2016-2026 (USD Billion)
25. Europe Biosimilars market, 2016-2026 (USD Billion)
26. Asia Pacific Biosimilars market, 2016-2026 (USD Billion)
27. Latin America Biosimilars market, 2016-2026 (USD Billion)
28. Middle East & Africa Biosimilars market, 2016-2026 (USD Billion)


Table Of Tables

List of Tables

1. Global Biosimilars market: snapshot
2. Drivers for Biosimilars market: impact analysis
3. Restraints for Biosimilars market: impact analysis
4. North America Biosimilars market revenue, by country, 2016-2026 (USD Billion)
5. North America Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
6. North America Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
7. North America Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
8. The U.S. Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
9. The U.S. Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
10. The U.S. Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
11. Rest of North America Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
12. Rest of North America Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
13. Rest of North America Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
14. Europe Biosimilars market revenue, by country, 2016-2026 (USD Billion)
15. Europe Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
16. Europe Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
17. Europe Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
18. U.K. Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
19. U.K. Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
20. U.K. Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
21. France Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
22. France Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
23. France Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
24. Germany Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
25. Germany Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
26. Germany Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
27. Rest of Europe Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
28. Rest of Europe Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
29. Rest of Europe Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
30. Asia Pacific Biosimilars market revenue, by country, 2016-2026 (USD Billion)
31. Asia Pacific Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
32. Asia Pacific Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
33. Asia Pacific Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
34. China Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
35. China Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
36. China Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
37. Japan Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
38. Japan Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
39. Japan Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
40. India Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
41. India Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
42. India Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
43. Rest of Asia Pacific Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
44. Rest of Asia Pacific Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
45. Rest of Asia Pacific Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
46. Latin America Biosimilars market revenue, by country, 2016-2026 (USD Billion)
47. Latin America Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
48. Latin America Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
49. Latin America Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
50. Brazil Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
51. Brazil Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
52. Brazil Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
53. Rest of Latin America Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
54. Rest of Latin America Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
55. Rest of Latin America Biosimilars market revenue, by Application, 2016-2026 (USD Billion)
56. Middle East & Africa Biosimilars market revenue, by Product, 2016-2026 (USD Billion)
57. Middle East & Africa Biosimilars market revenue, by Manufacturing type, 2016-2026 (USD Billion)
58. Middle East & Africa Biosimilars market revenue, by Application, 2016-2026 (USD Billion)


 

Methodology

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • paypal
  • amazon
  • visa
  • master card

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed